InnoTherapy "Presenting a New Global Standard for Digital Healthcare"

Digital Healthcare Vision Proclamation Ceremony

Innotherapy, a subsidiary of SCL Group, held a vision declaration ceremony and announced its vision and plans for the digital healthcare business.

On the 28th, Innotherapy announced that it held the 'Digital Healthcare Vision Declaration Ceremony' at the Glad Hotel in Yeouido, Seoul, targeting major domestic media outlets. The event was attended by Sun Ho-chang, CEO of Innotherapy, along with key executives from SCL Group and the company.

At this declaration ceremony, Innotherapy presented its new vision as a "global leader setting standards in the digital healthcare field through AI and big data." The company expressed its determination to leap forward as a global leading company in the digital healthcare business, which it is promoting as a new growth engine.

Innotherapy's digital healthcare business centers on overwhelming data superiority competitiveness. To this end, it plans to proactively invest in securing customer touchpoints and data capabilities in connection with group affiliates. Subsequently, it will implement a strategy to select attractive markets based on vast medical data and commercialize and preoccupy them.

Specific execution plans include ▲ securing a virtuous cycle structure where data is continuously generated ▲ building a platform capable of managing data with high quality ▲ establishing an open cooperation model with partner companies for innovative use of data. By 2025, after integrating group data and building the platform, the company will actively engage in non-face-to-face medical services, medical MyData, and medical AI (artificial intelligence) businesses.

Innotherapy will also simultaneously strive to improve its business and revenue structure. In the existing hemostatic agent sector, it plans to secure a foundation for sales expansion and operating profit turnaround through licensing contracts and technology transfers. Additionally, it will continuously consider M&A (mergers and acquisitions) to achieve stable performance.

CEO Sun Ho-chang stated, “Innotherapy, an affiliate of SCL Group, will lead the digital healthcare market, where there is no clear winner, by utilizing data from 300,000 annual health checkups, 50 million specimen tests, and a medical network of over 4,500 institutions.” He added, “To this end, we have invested in and established cooperative foundations with overseas related companies such as PhAST in the U.S. (diagnostic AI business) and H2U in Taiwan (AI healthcare platform business).”

He continued, “Through the full-scale launch of new businesses and global business expansion, we will innovate the sales structure centered on the data platform and leap forward as a global leading company in the digital healthcare field.”

Meanwhile, SCL Group, founded in 1983 with the establishment of SCL (Seoul Clinical Laboratories Foundation), a specialized testing institution, has grown into a comprehensive medical platform company with healthcare affiliates and subsidiaries such as Hanaro Medical Foundation, SCL Healthcare, and Ahels.